Navigation Links
PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors
Date:12/21/2009

ANNAPOLIS, Md., Dec. 21 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Jeffrey W. Runge, M.D. to PharmAthene's Board of Directors, increasing the Board to eight members.

Dr. Runge is a Principal at The Chertoff Group, a firm providing advisory services in business risk management, homeland security and homeland defense. He is also the President and founder of Biologue, Inc., which provides consulting in biodefense, medical preparedness and injury prevention and control. From 2001 through August of 2008, Dr. Runge served in the Bush administration, first as the head of the National Highway Traffic Safety Administration, confirmed by the Senate in August 2001. In September 2005, he became the Department of Homeland Security's first Chief Medical Officer and founded the DHS Office of Health Affairs in 2007. He was confirmed by the Senate as DHS' first Assistant Secretary for Health Affairs in December of 2007. Dr. Runge also served as Acting DHS Undersecretary for Science and Technology from February through August 2006. In his role at DHS, Dr. Runge oversaw the operations of the department's biodefense activities, medical preparedness and workforce health protection, including managing DHS' role in Project BioShield, working with the various federal departments on medical countermeasure assurance.

Prior to joining DHS, Dr. Runge was Assistant Chairman of the Department of Emergency Medicine at the Carolinas Medical Center in Charlotte, NC, from 1984 through 2001.

Dr. Runge earned his medical degree from the Medical University of South Carolina and his undergraduate degree from the University of the South.

"We are delighted to welcome Dr. Runge to t
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
2. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
3. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
4. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
5. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
6. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
7. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
8. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
9. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
10. PharmAthene Reports First Quarter 2009 Financial and Operational Results
11. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ... and forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Earlier this year in a June ... of the Adult Stem Cell Technology Center, LLC ( ... under appreciated unique property of adult tissue stem cells. ... Misunderstood in the Past, Important for the Future,” embodied ... He gave the address at the 4th World Congress ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Bio-Optronics, Inc. and flexcipio s.a. are pleased ... Bio-Optronics, Clinical Conductor Clinical Trial Management System (CTMS) ... This aligns the industry,s most comprehensive enterprise CTMS, ... with the best tools to optimize efficiency, productivity, ...
... European Trials Commencing for Injectable Biopolymer to Repair ... Symphony Medical, Inc., a developer of novel biopolymer ... patented flagship technology, Algisyl-LVR(R), was used on a ... 50-year-old male who was suffering from chronic heart ...
... BioVex Inc, a company developing next generation biologics for the ... that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 ... III and Stage IV melanoma had initiated. The study has ... United Kingdom, Germany and Australia due to open later in ...
Cached Biology Technology:Bio-Optronics Adds Innovative Electronic Data Capture (EDC) Solution to Clinical Conductor Clinical Trial Management System (CTMS), Continues to Improve Workflow and Productivity 2Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 2Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 3Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 4BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... a virus,s tiny exterior is a store of energy ... host cell, this pent-up energy is released, propelling the ... a virus factory. For the first time, Carnegie Mellon ... associated with the expulsion of viral DNA, a pivotal ...
... have found a critical piece in the evolutionary puzzle ... centuries ago. The team, from the School of ... developed into more complex cells and found this crucial ... previously thought. Team leader and ARC Federation ...
... A new study of children in Ukraine has found ... quality of care and the relationship between children and ... Based on their findings, the researchers highlight the importance ... relationships by changing caregivers, working schedules and providing training ...
Cached Biology News:Carnegie Mellon first to measure energy released from a virus during infection 2Carnegie Mellon first to measure energy released from a virus during infection 3An answer to another of life's big questions 2For HIV-infected children, quality of caregiver relationship is crucial 2